Secondary Lymphedema Clinical Trial
Official title:
A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in Combination With a Surgical Lymph Node Transfer for the Treatment of Patients With Secondary Lymphedema
Indicated for the Treatment of Secondary Lymphedema Associated with the Treatment of Breast Cancer. Primary objective is to evaluate the safety and tolerability of a single dose of Lymfactin® in patients with secondary lymphedema associated with the treatment of breast cancer.
This is an open label, multi-center, uncontrolled first in human trial that uses a standard 3 + 3 dose escalation scheme. Lymfactin® will be administered as a single dose by ex vivo perinodal injection into the fat pad of a flap of tissue containing lymph nodes from the abdominal wall. This flap of tissue will then be surgically implanted into the axillary region of the affected arm. This treatment with Lymfactin® may be performed in conjunction with or without breast reconstruction surgery. Up to two dose cohorts are planned to be included. Each dose of Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL: - Cohort 1: Lymfactin® [1 x 10E10 vp] - Cohort 2: Lymfactin® [1 x 10E11 vp] Should the dose escalation go up to Cohort 2 with initiation of a subsequent Extension Cohort a total of 15 - 21 patients may be treated in this study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03572998 -
Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment
|
N/A | |
Active, not recruiting |
NCT02895724 -
Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial
|
Phase 2 | |
Completed |
NCT04393168 -
Proof-of-concept Study of LymphMonitor 1.0 to Assess the Lymphatic Vessel Function
|
Phase 1 | |
Active, not recruiting |
NCT05441943 -
Lymphaticovenous Anastomosis as Treatment for Lymphedema
|
N/A | |
Active, not recruiting |
NCT03658967 -
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
|
Phase 2 | |
Completed |
NCT04897035 -
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Dayspring Active Wearable Compression Technology for Treating Lower Extremity Lymphedema
|
N/A | |
Recruiting |
NCT03578380 -
Supermicrosurgery for Breast Cancer Survivors With Lymphedema.
|
N/A | |
Completed |
NCT04045860 -
Complete Decongestive Therapy on Head and Neck Lymphedema
|
N/A | |
Active, not recruiting |
NCT03760744 -
Imaging Biomarkers of Lymphatic Dysfunction
|
N/A | |
Completed |
NCT03634462 -
Complete Decongestive Therapy With Negative Pressure for Lipedema and Lymphedema Therapy
|
N/A | |
Completed |
NCT03523494 -
Feasibility of Lymph Edema-induced Reticulation Subtraction Based on Computerized Tomography
|
||
Completed |
NCT01748604 -
Physical Therapies in the Decongestive Treatment of Lymphedema
|
N/A |